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Abstract: INTRODUCTION The Management of Myelomeningocele Study, a.k.a. the MOMS trial, was
published in 2011 in the New England Journal of Medicine. This prospective randomized controlled
trial proved to be a milestone publication that provided definitive evidence that fetal surgery is a novel
standard of care for select fetuses with spina bifida aperta (SB). The goal of our study is to assess whether
our center can match these benchmark results. MATERIALS AND METHODS Our study was conducted
according to the MOMS protocol using the same inclusion and exclusion criteria and looked at the same
outcome parameters that were used in the MOMS trial. Zurich and MOMS results were compared.
RESULTS We enrolled 20 patients between December 2010 and May 2015 all of whom underwent fetal
surgery for SB. Among 51 different outcome variables, there were only 3 favorable (multiplicity-adjusted)
significant differences (gestational age at birth, hindbrain herniation, and psychomotor development).
There were no statistically significant differences regarding any other parameters. CONCLUSION Our
findings confirm that rigorous apprenticeship, training, and comprehensive prospective data collection
enable centers like the Zurich Center for Fetal Diagnosis and Therapy to achieve benchmark results
for open fetal surgery for myelomeningocele and myeloschisis. These results justify the existence and
continuation of our program. Outcome documentation is an essential element of quality management. It
is medically and ethically fundamental for fetal medicine and surgery centers offering high-end innovative
medical care.
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Abstract
Introduction: The Management of Myelomeningocele 
Study, a.k.a. the MOMS trial, was published in 2011 in the 
New England Journal of Medicine. This prospective random-
ized controlled trial proved to be a milestone publication 
that provided definitive evidence that fetal surgery is a nov-
el standard of care for select fetuses with spina bifida aperta 
(SB). The goal of our study is to assess whether our center can 
match these benchmark results. Materials and Methods: 
Our study was conducted according to the MOMS protocol 
using the same inclusion and exclusion criteria and looked 
at the same outcome parameters that were used in the 
MOMS trial. Zurich and MOMS results were compared. Re-
sults: We enrolled 20 patients between December 2010 and 
Ueli Möhrlen and Nicole Ochsenbein-Kölble share first authorship, 
and Roland Zimmermann and Martin Meuli share last authorship. 
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May 2015 all of whom underwent fetal surgery for SB. Among 
51 different outcome variables, there were only 3 favorable 
(multiplicity-adjusted) significant differences (gestational 
age at birth, hindbrain herniation, and psychomotor devel-
opment). There were no statistically significant differences 
regarding any other parameters. Conclusion: Our findings 
confirm that rigorous apprenticeship, training, and compre-
hensive prospective data collection enable centers like the 
Zurich Center for Fetal Diagnosis and Therapy to achieve 
benchmark results for open fetal surgery for myelomeningo-
cele and myeloschisis. These results justify the existence and 
continuation of our program. Outcome documentation is an 
essential element of quality management. It is medically and 
ethically fundamental for fetal medicine and surgery centers 
offering high-end innovative medical care.
© 2019 S. Karger AG, Basel
Introduction
Experimental evidence from the fetal sheep model [1–
3] and from analyses of aborted human fetuses [4, 5] 
paved the way to open human fetal surgery for myelome-
ningocele (MMC; for simplicity, the abbreviation MMC 
stands for both myelomeningocele and its noncystic vari-
ant, called myeloschisis) [6, 7]. Based on encouraging re-
sults, a large prospective, randomized, human fetal sur-
gery clinical trial was carried out between 2003 and 2010 
in 3 US clinical centers, the Management of Myelomenin-
gocele Study (MOMS) [8]. The goal was to compare fetal 
versus postnatal surgery. The trial was stopped prema-
turely for better results in the fetal surgery group. The key 
findings of this milestone article, published in 2011 by 
The New England Journal of Medicine, were that fetal sur-
gery, although not curative, and although associated with 
maternal and fetal risks, represents a valid option of care. 
The primary benefits were a higher rate of reversal of 
hindbrain herniation, a significantly lower rate of shunt-
ing for hydrocephalus, and a significantly better rate of 
independent ambulation.
As a consequence of this breakthrough, the Zurich 
Center for Fetal Diagnosis and Therapy opened its own 
fetal surgery program in December 2010. As of this date, 
over 100 open fetal surgeries for MMC have been success-
fully performed. 
The MOMS results still represent the current bench-
mark. The goal of our study, therefore, was to investigate 
whether our program can replicate these reference re-
sults, as this would be vital quality information for both 
our center and our patients.
Materials and Methods
At the very beginning of our program, a data registry was cre-
ated to record all pertinent data in a prospective and comprehensive 
way. Of note, this registry includes, but is not limited to, the same 
demographic and 51 outcome variables as examined in the MOMS 
trial (the plan to carry out a comparative study to the MOMS trial 
was already established at the time of the center’s conception). All 
data for the present study were retrieved from this repository. The 
study was approved by our local Ethics Committee (KEK-ZH No. 
2015-0172), and parents gave written informed consent. 
Multidisciplinary diagnostic workup, application of inclusion 
and exclusion criteria, nondirective prenatal counselling, obtain-
ing written informed consent, perioperative management, as well 
as the maternal-fetal general anesthesia and surgery were basically 
done in accordance with the protocols and surgical techniques 
used during the MOMS trial.
All patients, irrespective of their country of origin, were sched-
uled to be re-hospitalized in our center at 34 weeks of gestation for 
expectant management and antepartum monitoring with the plan 
for elective caesarean section at 37 weeks.
After birth, babies were transferred to the multidisciplinary Pedi-
atric Spina Bifida Center (which is an integral part of the University 
Children’s Hospital Zurich) for standard baseline postnatal diagnos-
tic workup, setting up a patient (and family)-specific therapeutic reg-
imen, detailed instruction of parents, and preparation for a smooth 
transition to home after discharge. Subsequently, all patients were 
scheduled for routine follow-up appointments at our interdisciplin-
ary Pediatric Spina Bifida Center at 3, 6, 9, 12, 18, and 24 months after 
discharge (including but not limited to clinical examination by a mul-
tidisciplinary expert team, MRI, bladder and rectum manometry). 
Thereafter, follow-up appointments continue at yearly intervals up 
to 18 years of age. Developmental assessment was performed with the 
Bayley Scales of Infant and Toddler Development (Bayley III) [9]. 
For the purpose of this study, we were using the same result 
tables (structure and parameters/variables) as the ones published in 
the aforementioned New England Journal of Medicine article and 
entered our data to allow for direct numerical and statistical com-
parison. Our center’s first 20 patients undergoing fetal surgery for 
spina bifida aperta were enrolled from December 2010 to May 2015 
with a minimal follow-up of 24 months. End points to be compared 
were collected from follow-up appointments at 12 and 24 months. 
The prospectively collected dataset was complete with no loss of 
follow-up. Statistical analyses were done using SPSS version 23 for 
Windows. Differences in proportions were compared using the χ2 
test, and the significance level was set at p ≤ 0.05. If the counts were 
too low (predicted in the χ2 test < 5), the Fisher exact test was used 
instead of the χ2 test. In case of multiple tests, Bonferroni adjust-
ment was performed. The between-group comparison was per-
formed with the use of the Cochran-Armitage test for trend.
Results
From December 2010 through May 2015, 20 patients 
underwent fetal surgery for MMC repair. All infants were 
delivered by cesarean section in our center and included 












































































tient died on the first day of life (5%) due to unexplained 
severe lung hypoplasia and intractable respiratory failure.
All of the remaining 19 patients were examined ac-
cording to exactly the same parameters as used in the 
MOMS trial. The only deviation was that 15 of the 19 sur-
viving patients (4 were too young to be examined) under-
went neurodevelopmental assessment at 24 months in-
stead of at 30 months (see Discussion section). For all 
parameters, the Zurich data were compared with the 
MOMS data and statistically analyzed. All results are 
shown in Tables 1–4. The most relevant findings are com-
mented on below in the Discussion section.
Discussion
This is the first study from a non-MOMS center to rep-
licate the open fetal surgery arm of the MOMS trial to 
prove that benchmark results can be obtained outside the 
rigors of a clinical trial such as MOMS. When the MOMS 
trial was published, an editorial comment expressed skep-
ticism as to whether non-MOMS trial centers could de-
liver MOMS quality results [10]. We demonstrate that the 
Zurich Center for Fetal Diagnosis and Therapy has gener-
ated results that are at least equivalent to MOMS. 
For the sake of transparency, the following points hin-
der a “perfect” comparison: first, we compare 78 MOMS 
fetal surgery patients, treated between 2003 and 2010, 
with our first 20 fetal surgery patients, treated between 
2010 and 2015. Then, we disclose the partnership with the 
Department of Surgery of the Children’s Hospital of Phil-
adelphia (CHOP) and that 1 member of the CHOP fetal 
surgeons assisted in the treatment of our first 11 cases. 
Finally, developmental testing was performed at 24 
months with the newest Bayley version instead of at 30 
months as in the MOMS trial.
In the vast majority of variables, there was no statisti-
cally significant difference between our results and 
MOMS. Importantly, there were no significant differenc-
es regarding all 20 population characteristics (Table 1). 
For certain variables, we had unfavorable results com-
pared with the MOMS trial (Tables 2–4). Regarding ma-
ternal outcomes, we noted a higher rate of spontaneous 
labor (65 vs. 38%, p = 0.03). In terms of postneonatal out-
come, the only difference was a high incidence of epider-
moid cysts (28 vs. 3%, p = 0.004). Three out of 5 cases 
Table 1. Population characteristics
Characteristics MOMS (n = 78) Zurich (n = 20) p
Fetal sex female, n (%) 35 (45) 10 (50) 0.68
Maternal age at screening, years 29.3±5.3 30.4±4.8 0.40
Race or ethnic group, n (%) 0.28
White 73 (94) 17 (85)
Black 1 (1) 1 (5)
Hispanic 2 (3) 1 (5)
Other 2 (3) 1 (5)
Married or living with partner, n (%) 73 (94) 19 (95) 0.81
Years of schooling 14.8±1.7 N/A
Body mass index 26.2±3.7 26.2±4.1 1.0
Current smoker, n (%) 6 (8) 0 (0) 0.34
Either parent with familial history of neural tube defect, n (%) 8 (10) 0 (0) 0.20
Nullipara, n (%) 33 (42) 10 (50) 0.54
Previous uterine surgery, n (%) 11 (14) 2 (10) 1.00
Cervical length, mm 38.9±7.3 42.1±5.1 0.07
Anterior placenta, n (%) 36 (46) 11 (55) 0.48
Lesion level on ultrasonography, n (%) 0.49
Thoracic 4 (5) 0 (0)
L1–L2 21 (27) 3 (15)
L3–L4 30 (38) 11 (55)
L5–S1 23 (29) 6 (30)
Lesion level L3 or lower on ultrasonography, n (%) 53 (68) 17 (85) 0.13
Club foot on ultrasonography, n (%) 20 (26) 2 (10) 0.23
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underwent resection because of growth and/or symp-
toms, while 2 are being closely monitored. 
In the following domains, our results compare favorably 
with MOMS (Tables 2–4). Concerning neonatal outcomes, 
the gestational age at birth was significantly higher in the 
Zurich group than in MOMS (35.6 vs. 34.1 weeks, p < 
0.0001) with consequently higher birth weights (2,742 vs. 
2,383 g, p = 0.03) and lower rates of apnea (5 vs. 36%, p = 
0.006). We assume that these favorable findings result from 
using atosiban (Tractocile, Ferring AG, Baar, Switzerland), 
an extremely potent tocolytic not available in the USA [11].
Also, the Zurich patients demonstrate better results re-
garding cerebrospinal pathologies (Table 3). Complete 
hindbrain reversibility was found in 94% of our patients 
Table 2. Maternal outcome and fetal or neonatal outcome




Chorioamniotic membrane separation, n (%) 20 (26) 5 (25) 0.95 1.00
Pulmonary edema, n (%) 5 (6) 0 (0) 0.58 1.00
Oligohydramnios, n (%) 16 (21) 4 (20) 1.00 1.00
Placental abruption, n (%) 5 (6) 0 (0) 0.58 1.00
Gestational diabetes, n (%) 4 (5) 3 (15) 0.15 1.00
Chorioamnionitis, n (%) 2 (3) 0 (0) 1.00 1.00
Preeclampsia or gestational hypertension, n (%) 3 (4) 0 (0) 1.00 1.00
Spontaneous membrane rupture, n (%) 36 (46) 7 (35) 0.37 1.00
Spontaneous labor, n (%) 30 (38) 13 (65) 0.03 1.00
Blood transfusion at delivery, n (%) 7 (9) 0 (0) 0.34 1.00
Status of hysterotomy site at delivery, n/total n (%) 0.20a 1.00
Intact, well-healed 49/76 (64) 8/20 (40)
Very thin 19/76 (25) 10/20 (50)
Area of dehiscence 7/76 (9) 2/20 (10)
Complete dehiscence 1/76 (1) 0/20 (0)
Fetal or neonatal outcome
Bradycardia during fetal repair, n (%) 8 (10) 1 (5) 0.68 1.00
Perinatal death, n (%) 2 (3) 1 (5) 0.50 1.00
Gestational age at birth, weeks 34.1±3.1 35.6±9.2 <0.0001 <0.0001
Gestational age at birth, n (%) 0.04a 1.00
<30 weeks 10 (13) 0 (0)
30–34 weeks 26 (33) 5 (25)
35–36 weeks 26 (33) 8 (40)
≥37 weeks 16 (21) 7 (35)
Birth weight
Mean, g 2,383±688 2,742±393 0.03 1.00
Less than 3rd percentile, n (%) 0 1 (5) 0.20 1.00
Less than 10th percentile, n (%) 3 (4) 2 (10) 0.27 1.00
Dehiscence at repair site, n/total n (%) 10/77 (13) 1/20 (5) 0.45 1.00
Apnea, n/total n (%) 28/77 (36) 1/20 (5) 0.006 0.31
Pneumothorax, n/total n (%) 1/77 (1) 1/20 (5) 0.37 1.00
Respiratory distress syndrome, n/total n (%) 16/77 (21) 7/20 (35) 0.24 1.00
Patent ductus arteriosus, n/total n (%) 3/77 (4) 0/20 (0) 1.00 1.00
Sepsis, n/total n (%) 4/77 (5) 1/19 (5) 1.00 1.00
Necrotizing enterocolitis, n/total n (%) 1/77 (1) 0/19 (0) 1.00 1.00
Periventricular leukomalacia, n/total n (%) 4/77 (5) 0/20 (0) 0.58 1.00
Foot deformity, n/total n (%) 39/78 (50) 5/20 (25) 0.045 1.00
Values are means ± SD, unless otherwise indicated. a The between-group comparison was performed with the use of the Cochran-












































































versus in 36% of MOMS patients (p < 0.0001). A discrep-
ancy was found between shunt criteria met (in 55% of our 
patients vs. in 65% of MOMS patients, p = not significant 
[ns]) and patients actually shunted (the same 55% of our 
patients, but only 40% of the 65% of MOMS patients 
meeting the shunt criteria were shunted, p = ns), suggest-
ing a difference in neurosurgical practice between the 
MOMS trial centers and Zurich.
Neonatal foot deformities were present in 25% of Zu-
rich and in 50% of MOMS patients (p = 0.045) (Table 2). 
The comparison of the differences between motor func-
tion and anatomical levels yielded more favorable results 
for the Zurich cohort, but none reached statistical signif-
icance (Table 4).
Regarding independent walking and walking sta-
tus,  the results of the Zurich group were somewhat 
worse, but differences were not significant (Table 4). 
Taken together, there are no significant disparities re-
garding lower extremity motor function between the 2 
cohorts.
The last considerations regard postnatal development 
(Table 4). In contrast to the MOMS trial, our outcome as-
sessment was performed at 24 months and not at 30 
months using the third Bayley version. As results are ex-
pressed as standard scores (mean 100, 1 SD 15), no age 
effect is introduced. However, because of different nor-
mative samples, comparing results obtained from Bayley 
II (MOMS) with those from Bayley III (current study) is 
limited as scores tend to be higher with the Bayley III ver-
sion [12]. Despite these methodological aspects, the cog-
nitive outcome of our population is comparable to 
MOMS. 
Table 3. Infant outcome at 12 months
MOMS (n = 78) Zurich (n = 20) p Bonferroni-
adjusted 
p value
Primary outcome, n (%) 53 (68) 12 (60) 0.50 1.00
Components of the primary outcome, n (%) 0.06 1.00
Death before shunt placement 2 (3) 1 (5)
Shunt criteria met 51 (65) 11 (55)
Shunt placed without meeting criteria 0 0
Placement of shunt, n (%) 31 (40) 11 (100) 0.15 1.00
Any hindbrain herniation, n/total n (%) 45/70 (64) 1/18 (6) <0.0001 0.0005
Degree of hindbrain herniation, n/total n (%) <0.0001 0.005
None 25/70 (36) 17/18 (94)
Mild 28/70 (40) 1/18 (6)
Moderate 13/70 (36) 0/18 (0)
Severe 4/70 (19) 0/18 (0)
Any brainstem kinking, n/total n (%) 14/70 (20) 1/18 (6) 0.29 1.00
Degree of brainstem kinking, n/total n (%) 0.10a 1.00
None 56/70 (80) 17/18 (94)
Mild 4/70 (6) 1/18 (6)
Moderate 7/70 (10) 0/18 (0)
Severe 3/70 (4) 0/18 (0)
Abnormal location of fourth ventricle, n/total n (%) 32/70 (46) 2/18 (11) 0.01 0.51
Location of fourth ventricle, n/total n (%) 0.01a 0.51
Normal 38/70 (54) 16/18 (89)
Low 28/70 (40) 2/18 (11)
At foramen magnum 1/70 (1) 0/18 (0)
Below foramen magnum 3/70 (4) 0/18 (0)
Syringomyelia, n/total n (%) 27/69 (39) 9/18 (50) 0.40 1.00
Epidermoid cyst, n/total n (%) 2/67 (3) 5/18 (28) 0.004 0.2
Surgery for tethered cord, n/total n (%) 6/77 (8) 0/18 (0) 0.59 1.00
Chiari decompression surgery, n/total n (%) 1/77 (1) 0/18 (0) 1.00 1.00
Shunt infection, n/total n (%) 5/77 (6) 0/18 (0) 0.58 1.00
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Of note, all comparisons are based on the statistical 
results generated by the Fisher exact tests and the χ2 tests 
comparing single variables. Since we analyzed multiple 
outcome variables (n = 51), it was imperative to calculate 
a Bonferroni adjustment for multiplicity, leading to a 
substantial reduction of significant differences. The 3 fa-
vorable significant differences remaining are a higher 
gestational age at birth, less hindbrain herniation, and 1 
better parameter regarding psychomotor development 
(Tables 2–4).
Finally, Moldenhauer et al. [13] have recently pub-
lished the CHOP post-MOMS experience. They found 
that results were comparable to MOMS. When compar-
ing our results with Moldenhauer et al.’s, we find that they 
are comparable as well (Table 5). 
The above quoted post-MOMS article [13] also fuels a 
broader view: now, almost a decade after the completion 
of MOMS, it is time to gradually move beyond MOMS as 
a gold standard. This plea for new horizons embraces a 
fresh look at inclusion and exclusion criteria, testing nov-
el techniques, and also defining new standards based on 
proper results. In fact, we are addressing such issues in 
current studies enrolling more than 100 patients operated 
so far (December 2018).
Table 4. Outcomes of children at 30 months (MOMS) and at 24 months (Zurich cohort)
At 30 months,
MOMS (n = 64)
At 24 months,
Zurich (n = 15)
p Bonferroni-
adjusted p value
Primary outcome score 149±57.5 N/A (N/A) 0.02 1.00
Primary outcome components
Mental Development Index Bayley II 89.7±14 80.3±13.1a
Cognitive Composite Score Bayley III N/A (N/A) 92.9±10.3
Difference between motor function and anatomical levels 0.58±1.94 1.1±1.5 0.33 1.00
Mental Development Index Bayley II, n/total n (%)
≥50 60/62 (97) 15/15 (100) 1.00 1.00
≥85 46/62 (74) 6/15 (40) 0.02 1.00
Difference between motor function and anatomical levels, n/total n (%) 0.12b 1.00
≥Two levels better 20/62 (32) 5/14 (36)
One level better 7/62 (11) 4/14 (29)
No difference 14/62 (23) 4/14 (29)
One level worse 13/62 (21) 1/14 (7)
≥Two levels worse 8/62 (13) 0/14 (0)
Psychomotor Development Index Bayley II
Mean ± SD 64±17.4 65.7±7.7a 0.71 1.00
≥50, n/total n (%) 29/62 (47) 13/13 (100) <0.0001 0.02
≥85, n/total n (%) 10/62 (13) 1/13 (8) 0.68 1.00
Motor Composite Score Bayley III
Mean ± SD N/A (N/A) 75.6±5.3
≥50, n/total n (%) N/A (N/A) 12/12 (100)
≥85, n/total n (%) N/A (N/A) 1/12 (8)
Peabody Development Motor Scale
Stationary score 7.4±1.1 N/A (N/A)
Locomotion score 3±1.8 N/A (N/A)
Object manipulation score 5.1±2.6 N/A (N/A)
Walking independently on examination, n/total n (%) 26/62 (42) 2/14 (14) 0.053 1.00
Walking status, n/total n (%) 0.45b 1.00
None 28/62 (29) 5/14 (36)
Walking with orthotics or devices 18/62 (29) 7/14 (50)
Walking without orthotics 26/62 (42) 2/14 (14)
WeeFIM score
Self-care 20.5±4.2 N/A (N/A)
Mobility 19.9±6.4 N/A (N/A)
Cognitive 23.9±5.2 N/A (N/A)
Values are means ± SD, unless otherwise indicated. a Calculated based on the suggested transformation by Jary et al. [14]. b The between-group comparison 












































































In conclusion, the Zurich Center for Fetal Diagnosis 
and Therapy has generated benchmark results regarding 
open fetal surgery for MMC. This finding justifies the ex-
istence and, in particular, continuation of our program. 
More generally, these results confirm that with rigorous 
apprenticeship, training, and fastidious attention to de-
tailed, well-delineated, and prospective data collection on 
every case it is possible for centers like the Zurich Center 
for Fetal Diagnosis and Therapy to deliver benchmark 
results for open fetal surgery for MMC. Finally, compre-
hensive outcome documentation is medically and ethi-
cally imperative. It is an instrumental element of quality 
management for fetal medicine and surgery centers offer-
ing high-end innovative medical care.
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Table 5. Comparison of key findings of single-center post-MOMS [13] data with Zurich Center data
CHOP [13] (n = 100) Zurich (n = 20)
Membrane separation, % 22.9 25.0
Preterm premature rupture of membranes, % 32.3 35.0
Preterm labor, % 37.5 65.0
Average gestational age at delivery, weeks 34.3 35.6
Rate of perinatal loss, % 6.1 5.0
Woman received transfusions, % 3.4 0.0
Neonates with no evidence of hindbrain herniation on MRI, % 71.1 94.0
Children with a functional level of ≥1 better than the prenatal anatomical level, % 55.0 60.0
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